Immune checkpoint inhibitors, including anti-CTLA4 and anti-PD-1, restore the immune system by “removing the brake”, promoting CD8-positive T-cells anti-cancer activity, enabling tumor regression and long-term cancer control in up to 50% of patients [36,37,38]. Here, CTLA4 is linked to cancer.